We wish to focus on severe drug-induced adverse events, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug-induced liver injury. These reactions are critical adverse events and are reasons for drug withdrawals and termination of drug development. By focusing on important adverse events that are frequently observed in certain regions and/or populations, we could identify useful markers that can reduce or prevent adverse reactions in these populations. These efforts are expected to yield important results with very positive implications for public health as it can improve the quality of life, as well as help towards reducing healthcare costs.
Members of this working group seeks to engage into multicenter collaboration to identify patients groups presenting a variety of adverse reactions from a diverse population background to delineate the variability of the adverse reactions with the underlying genetic background.